Division of Cardiac Surgery, University of Verona Medical School, Verona, Italy.
Division of Cardiac Surgery, University of Verona Medical School, Verona, Italy.
Ann Thorac Surg. 2021 Jul;112(1):e21-e22. doi: 10.1016/j.athoracsur.2020.10.062. Epub 2021 Jan 4.
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has been popularized as an attractive alternative to redo surgical aortic valve replacement for bioprosthetic valve dysfunction. Acute valve thrombosis has been occasionally described after ViV-TAVR. Lack of anticoagulant therapy has been always considered a crucial risk factor. This report describes a rare case of early postoperative fatal ViV-TAVR thrombosis despite adequate anticoagulation in addition to dual antiplatelet therapy.
经导管主动脉瓣置换术中置入的瓣膜(ViV-TAVR)已成为治疗生物瓣功能障碍再次行主动脉瓣置换术的一种有吸引力的替代方法。ViV-TAVR 后偶尔会出现急性瓣膜血栓形成。缺乏抗凝治疗一直被认为是一个关键的危险因素。本报告描述了一例罕见的术后早期 ViV-TAVR 血栓形成病例,尽管在双联抗血小板治疗的基础上进行了充分的抗凝治疗,但仍导致了致命后果。